Nuwellis Updates Investor Presentation, Citing 13% YTD Revenue Growth

Nuwellis updated its investor presentation, reporting 13% YTD revenue growth, 72% gross margin, and a cash runway through Q2 2027. The company highlighted a $4.4B U.S. market opportunity and upcoming product launches, including SmartView and Pressure IQ. Nuwellis also seeks FDA clearance for Aquadex's expanded pediatric use.

Original reporting
Published Nov 17, 2026, 1:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nuwellis Updates Investor Presentation, Citing 13% YTD Revenue Growth — source image
Decision brief

The 30-second read

$NUWEBullishLow
01

Why it matters

For traders, the main value is near-term visibility into growth, gross margin, and liquidity, plus concrete pipeline milestones (SmartView, Pressure IQ, ClarityPRIME) and a specific regulatory filing (510(k) for Aquadex pediatric indication).

02

Market read

The update can influence sentiment and positioning in NUWE by reinforcing growth and liquidity visibility, while regulatory clearance uncertainty limits upside conviction.

03

What to watch

ClarityPRIME is explicitly not FDA cleared, and the pediatric Aquadex expansion is tied to a 510(k) submission, so execution and regulatory timing remain key swing factors.

Relevance 5/10Novelty 5/10Timing: today’s SEC 8-K investor-presentation update

Background

The article summarizes an updated investor presentation filed via an SEC 8-K, focusing on financial progress, cash runway, and device pipeline/regulatory steps.

Company-level read

Ticker impact

$NUWEBullishMedium confidence
Context

Nuwellis filed an updated investor presentation citing 13% YTD revenue growth, 72% gross margin, and cash runway through Q2 2027.

Expected impact

Likely modest positive bias as investors price in improved financial trajectory and clearer product timelines, tempered by regulatory uncertainty.

Evidence & confidence

This is a company-specific SEC 8-K update with multiple quantified operating metrics and explicit regulatory submission and launch timing, but it is not a clinical readout or approval that would typically drive a large repricing.

Market effects

Incremental read-through for medical device investors on how companies communicate margin progress and regulatory timelines.

none

none

Counterpoint

Investors may discount the presentation because it is not a new clinical outcome or FDA decision, and runway claims can be sensitive to burn rate assumptions.

Key entities

  • Nuwellis, Inc.

    US-listed medical device company updating investors on YTD growth, margins, cash runway, and regulatory/product pipeline milestones.

Related articles

$NUWEMed

Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in…

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss Console unit sales increased 88% year-to-date versus pri

$NUWEHighAI 8/10

Nuwellis submits FDA application for pediatric Aquadex expansion

Nuwellis (NASDAQ: NUWE) submitted a 510(k) application to the FDA to expand the use of its Aquadex SmartFlow System to pediatric patients weighing 5 kg and above, currently cleared for 20 kg and above. The submission includes clinical data from the ULTRA-Peds Registry and aims to provide treatment options for fluid overload in smaller children. The company's CEO and a medical director commented on the strategic importance and clinical benefits of the expansion.

$NUWEMed

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 13, 2026 Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin Recent capital raise and warrant exercises extend cash runway through second quarter

$NUWEMed

Nuwellis Slumps on Share Sale

Nuwellis (NASDAQ: NUWE) entered a definitive securities purchase agreement for a registered direct offering of 1,310,890 shares at $2.59 per share, with gross proceeds of about $3.1 million from warrant exercises tied to its June 2026 offering. In a concurrent private placement, investors receive warrants for up to 1,310,890 shares at $2.59, exercisable immediately, expiring in five years. Closing expected around Aug. 3, 2026.

$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.